Neil Gagnon Buys 10,642 Shares of CareDx, Inc. (CDNA) Stock
CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon bought 10,642 shares of the stock in a transaction dated Thursday, October 5th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $42,568.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Thursday, September 7th, Neil Gagnon purchased 6,496 shares of CareDx stock. The shares were acquired at an average cost of $3.05 per share, for a total transaction of $19,812.80.
- On Monday, August 28th, Neil Gagnon purchased 21,448 shares of CareDx stock. The shares were acquired at an average cost of $2.77 per share, for a total transaction of $59,410.96.
- On Friday, August 25th, Neil Gagnon purchased 35,119 shares of CareDx stock. The shares were acquired at an average cost of $2.92 per share, for a total transaction of $102,547.48.
- On Monday, July 24th, Neil Gagnon purchased 1,486 shares of CareDx stock. The shares were acquired at an average cost of $1.23 per share, for a total transaction of $1,827.78.
Shares of CareDx, Inc. (NASDAQ CDNA) opened at 5.62 on Friday. The company’s 50-day moving average is $3.18 and its 200-day moving average is $1.69. The stock’s market cap is $126.68 million. CareDx, Inc. has a 1-year low of $0.76 and a 1-year high of $6.69.
CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. The company had revenue of $12.05 million for the quarter, compared to analysts’ expectations of $11.87 million. Equities analysts expect that CareDx, Inc. will post ($0.82) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/08/neil-gagnon-buys-10642-shares-of-caredx-inc-cdna-stock.html.
Institutional investors and hedge funds have recently made changes to their positions in the business. Royce & Associates LP boosted its stake in CareDx by 23.5% during the 1st quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock worth $737,000 after purchasing an additional 100,111 shares during the last quarter. Gagnon Securities LLC raised its holdings in shares of CareDx by 2.9% during the 2nd quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after acquiring an additional 57,954 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of CareDx during the 2nd quarter worth $212,000. 29.15% of the stock is currently owned by institutional investors.
A number of equities research analysts recently issued reports on CDNA shares. Raymond James Financial, Inc. raised shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, September 27th. Zacks Investment Research raised shares of CareDx from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Tuesday, September 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $7.00 price target (up previously from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. Finally, ValuEngine raised shares of CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.